S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:ALXO

ALX Oncology (ALXO) Stock Price, News & Analysis

$15.85
-0.20 (-1.25%)
(As of 02/23/2024 ET)
Today's Range
$15.66
$16.29
50-Day Range
$12.59
$16.79
52-Week Range
$3.94
$17.42
Volume
213,177 shs
Average Volume
295,164 shs
Market Capitalization
$789.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.07

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
26.6% Upside
$20.07 Price Target
Short Interest
Bearish
13.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$36,951 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.61) to ($3.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.32 out of 5 stars

Medical Sector

753rd out of 939 stocks

Pharmaceutical Preparations Industry

353rd out of 439 stocks


ALXO stock logo

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

ALXO Stock News Headlines

ALX Oncology (NASDAQ:ALXO) Stock Price Down 5.4%
ALX Oncology Holdings Inc.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
ALX Oncology: Major Caution Warranted Moving Forward
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
ALX Oncology (NASDAQ: ALXO)
Piper Sandler Keeps Their Buy Rating on ALX Oncology Holdings (ALXO)
What's Going On With ALX Oncology Stock?
ALX Oncology Announces Pricing of Public Offering
ALX Oncology Announces Proposed Public Offering
The Latest Analyst Ratings for ALX Oncology Holdings
See More Headlines
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
2/23/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
71
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.07
High Stock Price Target
$34.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+24.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-123,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.46 per share

Miscellaneous

Free Float
24,760,000
Market Cap
$801.60 million
Optionable
Optionable
Beta
1.65
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Corey S. Goodman Ph.D. (Age 73)
    Executive Chairman
    Comp: $84k
  • Mr. Jason W. LettmannMr. Jason W. Lettmann (Age 47)
    CEO & Director
    Comp: $60.5k
  • Dr. Jaume Pons Ph.D. (Age 58)
    Founder, President, Director & Chief Scientific Officer
    Comp: $856.29k
  • Mr. Peter S. Garcia M.B.A.Mr. Peter S. Garcia M.B.A. (Age 62)
    Chief Financial Officer
    Comp: $631.11k
  • Dr. Sophia Randolph M.D. (Age 56)
    Ph.D., Chief Medical Officer & Director
    Comp: $637.24k
  • Dr. Michael Chang Ph.D.
    Vice President of Operations
  • Ms. Shelly Pinto (Age 48)
    Senior VP of Finance & Chief Accounting Officer
    Comp: $508.26k
  • Dr. Christopher Byrd J.D.
    Ph.D., General Counsel
  • Dr. Athanasios Tsiatis M.D.
    Senior Vice President of Clinical Development
  • Dr. Lin Yeong-Liang M.D.
    M.S., Senior Vice President of Drug Safety & Pharmacovigilance














ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALXO shares.
View ALXO analyst ratings
or view top-rated stocks.

What is ALX Oncology's stock price target for 2024?

8 Wall Street analysts have issued 12-month price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they expect the company's share price to reach $20.07 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price.
View analysts price targets for ALXO
or view top-rated stocks among Wall Street analysts.

How have ALXO shares performed in 2024?

ALX Oncology's stock was trading at $14.89 on January 1st, 2024. Since then, ALXO stock has increased by 6.4% and is now trading at $15.85.
View the best growth stocks for 2024 here
.

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ALXO earnings forecast
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.13.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did ALX Oncology IPO?

(ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vestal Point Capital LP (3.32%), Vanguard Group Inc. (3.02%), Point72 Asset Management L.P. (1.83%), Price T Rowe Associates Inc. MD (1.09%), Price T Rowe Associates Inc. MD (1.09%) and Northern Trust Corp (0.49%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends
.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 2/23/2024 by MarketBeat.com Staff